Leerink Partners Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock

Posted by George Bondi on Oct 29th, 2026

Replimune Group (NASDAQ:REPL – Get Free Report) had its target price lifted by research analysts at Leerink Partners from $19.00 to $31.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s target price would suggest a potential upside of 80.81% from the stock’s current price.

REPL has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Finally, Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $14.33.

View Our Latest Stock Report on Replimune Group

Replimune Group Stock Performance

Shares of REPL traded up $1.08 during mid-day trading on Thursday, reaching $17.14. 3,602,239 shares of the company’s stock traded hands, compared to its average volume of 4,325,783. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The business’s 50-day moving average price is $13.46 and its 200-day moving average price is $9.25. The stock has a market capitalization of $1.61 billion, a P/E ratio of -5.46 and a beta of 0.93. Replimune Group has a 12 month low of $1.50 and a 12 month high of $17.57.

Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. Equities analysts predict that Replimune Group will post -2.82 earnings per share for the current year.

Insider Transactions at Replimune Group

In other news, CFO Emily Hill sold 11,448 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the completion of the sale, the chief financial officer owned 225,108 shares in the company, valued at $2,919,650.76. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider owned 224,215 shares of the company’s stock, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 79,124 shares of company stock valued at $1,038,364. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of REPL. AXQ Capital LP lifted its holdings in shares of Replimune Group by 4.1% during the second quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after purchasing an additional 1,056 shares during the last quarter. Walleye Capital LLC boosted its position in shares of Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after purchasing an additional 2,192 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Replimune Group by 30.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after purchasing an additional 4,050 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Replimune Group in the 3rd quarter worth about $64,000. Finally, Allworth Financial LP acquired a new stake in Replimune Group during the 2nd quarter worth about $62,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

Positive Sentiment: Quarterly loss was narrower than expected: Replimune reported a fiscal second-quarter loss of $0.54 per share, beating the consensus estimate for a $0.78 loss. The result may have improved sentiment despite the company remaining unprofitable. Replimune earnings results
Positive Sentiment: Early TUDRIQEV adoption is encouraging: More than 15 institutions prescribed TUDRIQEV within 20 business days, after the therapy was first delivered to patients on October 6. The initial prescribing activity supports expectations for a faster commercial ramp. Replimune corporate update
Positive Sentiment: Solid liquidity supports the launch: Replimune ended the quarter with $307.8 million in cash, providing funding for commercialization and clinical development while management works to expand TUDRIQEV’s market presence. Replimune long-term investor takeaways
Neutral Sentiment: Permanent reimbursement code remains a future catalyst: Management anticipates receiving a permanent J-code for TUDRIQEV by April 2027. The code could simplify reimbursement and support adoption, but it has not yet been granted. Replimune J-code update
Negative Sentiment: Replimune continues to generate losses: The earnings beat reflects lower-than-expected losses rather than profitability, leaving the company dependent on successful TUDRIQEV commercialization and continued access to capital.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.